SCHEMBL6804641

SCHEMBL6804641

Cc1ccc(-c2ccc(N(C)C)cc2)c(C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
CSNK2A1 P68400 1/20 0.47
ALDH1A1 P00352 2/20 0.44
TSHR P16473 1/20 0.44
CYP46A1 Q9Y6A2 1/20 0.43
MCL1 Q07820 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6804144 0.90 HSD17B10 (0.49) HSD17B10SMN1; SMN2CSNK2A1ALDH1A1TSHR
SCHEMBL6799120 0.87 HDAC7 (0.49) SMN1; SMN2CSNK2A1ALDH1A1TSHRMCL1
SCHEMBL6495696 0.86 HSD17B10 (0.58) HSD17B10SMN1; SMN2CSNK2A1ALDH1A1CYP46A1
SCHEMBL17394735 0.83 HSD17B10 (0.47) HSD17B10SMN1; SMN2ALDH1A1HDAC1HDAC6
SCHEMBL3733709 0.81 HDAC7 (0.60) HSD17B10SMN1; SMN2CSNK2A1ALDH1A1CYP46A1
SCHEMBL6804716 0.81 MCL1 (0.46) HSD17B10SMN1; SMN2CSNK2A1ALDH1A1TSHR
SCHEMBL6639090 0.80 FOLH1 (0.53) HSD17B10SMN1; SMN2ALDH1A1FOLH1MEN1
SCHEMBL27999421 0.80 HSD17B10 (0.51) HSD17B10SMN1; SMN2CSNK2A1CYP46A1MCL1
SCHEMBL6492370 0.80 HSD17B10 (0.51) HSD17B10SMN1; SMN2CSNK2A1ALDH1A1CYP46A1
SCHEMBL6499129 0.80 HSD17B10 (0.51) HSD17B10SMN1; SMN2CSNK2A1ALDH1A1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 HSD17B10 148/4885SMN1; SMN2 1854/4885CSNK2A1 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.